RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00035024.xml
PDF herunterladen
Thromb Haemost 2013; 110(01): 04
DOI: 10.1160/TH13-05-0362
DOI: 10.1160/TH13-05-0362
Invited Editorial Focus
Dabigatran has the upper hand on warfarin
Weitere Informationen
Publikationsverlauf
Received:
03. Mai 2013
Accepted:
03. Mai 2013
Publikationsdatum:
30. November 2017 (online)
Editorial Focus on Sun et al. Thromb Haemost 2013; 110: 153-161.
-
References
- 1 Deedwania P, Huang G. An update on antithrombotic therapy in atrial fibrillation: The role of newer and emergent drugs. Rev Cardiovasc Med 2012; 13: 104.
- 2 Connolly S, Ezekowitz M, Yusuf S. et al. Committee R-LS, Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. New Engl J Med 2009; 361: 1139-1151.
- 3 Watanabe M, Siddiqui F, Qureshi A. Incidence and management of ischemic stroke and intracerebral hemorrhage in patients on dabigatran etexilate treatment. Neurocritical Care 2012; 16: 203-209.
- 4 Sun L, Zhou W, Ploen R. et al. Anticoagulation with dabigatran does not increase secondary intracerebral haemorrhage after thrombolysis in experimental cerebral ischaemia. Thromb Haemost 2013; 110: 153-161.